University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...
Acute myeloid leukemia (AML) does more than infiltrate the lungs: it also transforms lung tissue to create an inflammatory ...
Neighborhood disinvestment, characterized by infrastructure deterioration, is linked to increased stress and adverse cancer outcomes, necessitating further research. Racial disparities in acute ...
Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue and cause ...
Stocktwits on MSN
SLS, IBRX eye green month as biotech ETF gains steam: Analyst sees ‘continued opportunities’ in immuno-oncology
Edison Investment Research said oncology still offers “continued opportunities” across immuno-oncology, targeted therapies ...
While several targeted therapies are approved for acute myeloid leukemia, a 2023 U.K. study found that median survival following diagnosis was only about seven months, highlighting the need not only ...
Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute ...
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...
The University of Warwick, which is setting up the Registry, plans to collect data for analysis from 500 AML patients at sites in 30 large metropolitan NHS hospitals across the UK by the end of this ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy. A team of researchers from Colombia Engineering and Irving Institute for Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results